期刊文献+

两种帕罗西汀(乐友与赛乐特)治疗抑郁症疗效及安全性 被引量:15

A comparative study of domestic and imported proucts of paroxetine on efficacy and safety in patients with major depression
下载PDF
导出
摘要 目的比较国产帕罗西汀(乐友)与进口帕罗西汀(赛乐特)治疗抑郁症的临床疗效及安全性。方法研究采用随机、双盲、活性药物(赛乐特)对照的方法,多中心入组,治疗周期为8周。共完成临床观察210例(乐友组106例、赛乐特组104例)。采用汉密尔顿抑郁量表(HAMD)和汉密尔顿焦虑量表(HAMA)评定疗效,以生命体征、实验室检查、ECG的改变和不良事件的发生率评价安全性。结果两组HAMD、HAMA评分治疗后均有明显下降,乐友组有效率为81.1%,赛乐特组有效率为80. 7%,两组间疗效无显著差异。乐友组不良事件发生率为32.1%,赛乐特组为36.5%,两组无显著性差异。结论乐友治疗抑郁症安全有效,与赛乐特比较无显著性差异。 Objective: To compare the clinical efficacy and safety of domestic paroxetine(Leyou) in the treatment on major depression with seroxat . Methods: A 8 -week double -blind multicentre study compared Leyou(20mg/d, n = 106)with seroxat(20mg/d, n = 104) in 210 patients with major depression. To assess the efficacy and safety by using Hamilton rating scale for depression and anxiety (HAMD and HAMA ), biochemical index, electrocardiogram and the rate of adverse events. Results: 1 ) The Leyou group : the scroes of the HAMD and HAMA after treatment (5.9 ± 5.0; 4.9 ± 4.3 ) were significantly lower than the baseline (26. 4±6.8; 24.2±8.1) (P〈0.001), the rate the HAMD of score decreasing that was over 50% was 81.1% ; the seroxat group: the scroes of HAMD and HAMA after treatment (5.7 ± 5.4; 5.0 ± 5.3 ) were significantly lower than the baseline (26.4 ± 6.3; 24.1 ± 8.2) (P 〈 0. 001 ), the rate the HAMD of score decreasing that was over 50% was 80.7%. 2) After 8 - week treated, there was no significant difference on the rate of adverse events between the two groups (P 〉 0.05 ). Conclusion:The Leyou would effectively improve the symptoms of the patients with major depression; moreover, there were no significant difference on efficacy and safety between the Leyou and seroxat.
出处 《上海精神医学》 2005年第6期334-336,共3页 Shanghai Archives of Psychiatry
关键词 帕罗西汀 抑郁症 Paroxetine Major depression
  • 相关文献

参考文献10

  • 1Shigeru M, Seizaburo A. Differential effects of milnaeipran, fluvoxamine and paroxetine for inhibited and agitated depression. European Psychiatry, 2004,19 : 450 - 451.
  • 2Shigeru M, Seizaburo A. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender. European Psychiatry, 2003,18:418-420.
  • 3Dorotea MS, Nela P, Marina S, et al. The effects of paroxetine and tianeptine on peripheral biochemical markers in major depression. Progress in Neuro - Psychopharmacology & Biological Psychiatry, 2002,26:1235- 1243.
  • 4Daniel S, Pierre V, Emmanuel W, et al. A comparative study of milnacipran and paroxetine in outpatients with major depression. Journal of Affective Disorders, 2004,83 : 233 - 236.
  • 5张晓建,包静.赛乐特治疗抑郁症效果分析[J].现代康复,2000,4(6):933-933. 被引量:4
  • 6张迎黎,张建宏,梁炜,张朝辉,李战文.文拉法辛缓释剂和帕罗西汀治疗抑郁症的对照研究[J].上海精神医学,2003,15(6):341-343. 被引量:17
  • 7Vetoer K, Colleen M, Sidney K, et al. EEG correlates of acute and chronic paroxetine treatment in depression. Journal of Affective Disorders, 2002,69:241 - 249.
  • 8姚道元,成文琴,龚震明.赛乐特治疗抑郁症及其躯体化症状的临床疗效分析[J].四川精神卫生,2000,13(3):199-200. 被引量:2
  • 9Jun - ichi lga, Shu - ichi Ueno, Ken Yamauchi, et al. Serotonin transporter mRNA expression in peripheral leukocytes of patients with major depression before and after treatment with paroxetine. Neuroscience Letters, 2005,389 : 12 - 16.
  • 10杨保胜,田克龙.国产乐友和进口赛乐特治疗抑郁症对照研究[J].临床医药实践,2004,13(11):841-842. 被引量:2

二级参考文献15

  • 1[2]Judge R, Once-daily venlafaxine extended release (XR) vs. fluoxetine for the treatment of depression. J Clin Psychiatry,2001,62( 11 ):888 ~ 893
  • 2[3]Kaplan EM. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained of on response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study. Clin Ther,2002, 24(7): 1194~1200
  • 3[4]Rusolph RL. Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reupatake inhibitors. Acta Psychiatr Scand Suppl, 2002, (415) : 24 ~30
  • 4[6]Wellingon K, Perry CM. Venlafaxine extended-release: a review of its use in the management of major depression. CNS Drugs, 2001, 15 (8) : 643 ~669
  • 5[7]Silverstone PH, Entsuah R, Hackett D. Two items on the Hamilton Depression rating scale are effective predictors of remission: comparison of selective serotonin reuptake inhibitors with the combined serotonin/norepinephrine reuptake inhibitor, venlafaxine. Int Clin Psychopharmacol, 2002, 17(6) : 273 ~280
  • 6[8]Momtgomery SA, Mahe V, Hardiquet V, et al. Effectiveness of venlafaxine, extended release formulation, in the short-term and longterm treatment of generalized anxiety disorder: results of a survival analysis. J Clin Psychopharmacol, 2002, 22(6) : 561 ~567
  • 7[9]Ables AZ, Baughman OL. Antidepressants: update on new agents and indications. Am Fam Physician, 2003, 67 (3) : 547 ~ 554
  • 8[10]Altshuler L, Suppes T, Black D, et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry, 2003, 160 (7) : 1252~1262
  • 9[11]Yatham LN, Calabrese JR, Kusumakar V. Bipolar depression: criteria for treatment selection, definition of refractoriness, and treatment options. Bipolar Disord, 2003, 5(2) : 85~97
  • 10[12]Grunze H, Schlosser S, Walden J. New perspectives in the acute treatment of bipolar depression. world J Biol Psychiatry,2000,1 ( 3 ):129 ~ 136

共引文献19

同被引文献106

引证文献15

二级引证文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部